Cholinergic neuronal defect without cell loss in Huntington's disease

Human Molecular Genetics

Volumn 15, Issue 21, 2006, Pages 3119-3131

  Smith, Ruben ^a   Chung, Hinfan ^a   Rundquist, Sara ^a   Maat Schieman, Marion L C ^b   Colgan, Lesley ^c   Englund, Elisabet ^d   Liu, Yong Jian ^c   Roos, Raymund A C ^b   Faull, Richard L M ^e   Brundin, Patrik ^a   Li, Jia Yi ^a  

^a LUND UNIVERSITY   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; HUNTINGTIN; MESSENGER RNA; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VESICULAR ACETYLCHOLINE TRANSPORTER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL LOSS; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPINAL CORD; STEREOMETRY; TRANSGENIC MOUSE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CASE-CONTROL STUDIES; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MALE; MAZE LEARNING; MEMBRANE TRANSPORT PROTEINS; MEMORY; MICE; MICE, TRANSGENIC; MOTOR ENDPLATE; MUSCULAR ATROPHY; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHYSOSTIGMINE; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

MUS MUSCULUS;

EID: 33750201279     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddl252     Document Type: Article

References (46)

1. Group, H.s.D.C.R. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
2. Goldberg, Y.P., Telenius, H. and Hayden, M.R. (1994) The molecular genetics of Huntington's disease. Curr. Opin. Neurol., 7, 325-332.
3. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
4. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
5. Vonsattel, J.P. and DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
6. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P., Jr. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
7. Calabresi, P., Centonze, D., Pisani, A., Sancesario, G., Gubellini, P., Marfia, G.A. and Bernardi, G. (1998) Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease. Ann. Neurol., 43, 586-597.
8. Davies, S.W. and Roberts, P.J. (1988) Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum. Neuroscience, 26, 387-393.
9. Ferrante, R.J., Beal, M.F., Kowall, N.W., Richardson, E.P., Jr and Martin, J.B. (1987) Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res., 411, 162-166.
10. Aquilonius, S.M., Eckernas, S.A. and Sundwall, A. (1975) Regional distribution of choline acetyltransferase in the human brain: Changes in Huntington's chorea. J. Neurol. Neurosurg. Psychiatry, 38, 669-677.
11. Bird, E.D. and Iversen, L.L. (1974) Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain, 97, 457-472.
12. Lange, K.W., Javoy-Agid, F., Agid, Y., Jenner, P. and Marsden, C.D. (1992) Brain muscarinic cholinergic receptors in Huntington's disease. J. Neurol., 239, 103-104.
13. Spokes, E.G. (1980) Neurochemical alterations in Huntington's chorea: A study of post-mortem brain tissue. Brain, 103, 179-210.
14. Suzuki, M., Desmond, T.J., Albin, R.L. and Frey, K.A. (2001) Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers. Synapse, 41, 329-336.
15. Vetter, J.M., Jehle, T., Heinemeyer, J., Franz, P., Behrens, P.F., Jackisch, R., Landwehrmeyer, G.B. and Feuerstein, T.J. (2003) Mice transgenic for exon 1 of Huntington's disease: Properties of cholinergic and dopaminergic pre-synaptic function in the striatum. J. Neurochem., 85, 1054-1063.
16. Aquilonius, S.M. and Eckernas, S.A. (1977) Choline therapy in Huntington chorea. Neurology, 27, 887-889.
17. Aquilonius, S.M. and Sjostrom, R. (1971) Cholinergic and dopaminergic mechanisms in Huntington's chorea. Life Sci. I, 10, 405-414.
18. Tarsy, D., Leopold, N. and Sax, D.S. (1974) Physostigmine in choreiform movement disorders. Neurology, 24, 28-33.
19. Fernandez, H.H., Friedman, J.H., Grace, J. and Beason-Hazen, S. (2000) Donepezil for Huntington's disease. Mov. Disord., 15, 173-176.
20. de Tommaso, M., Specchio, N., Sciruicchio, V., Difruscolo, O. and Specchio, L.M. (2004) Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov. Disord., 19, 1516-1518.
21. Rot, U., Kobal, J., Sever, A., Pirtosek, Z. and Mesec, A. (2002) Rivastigmine in the treatment of Huntington's disease. Eur. J. Neurol., 9, 689-690.
22. Morton, A.J., Hunt, M.J., Hodges, A.K., Lewis, P.D., Redfern, A.J., Dunnett, S.B. and Jones, L. (2005) A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur. J. Neurosci., 21, 855-870.
23. Li, J.Y., Popovic, N. and Brundin, P. (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx, 2, 447-464.
24. Shimojo, M. and Hersh, L.B. (2004) Regulation of the cholinergic gene locus by the repressor element-1 silencing transcription factor/neuron restrictive silencer factor (REST/NRSF). Life Sci., 74, 2213-2225.
25. Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B.R., Hayden, M.R., Timmusk, T. et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet., 35, 76-83.
26. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A. et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA, 100, 2041-2046.
27. Ribchester, R.R., Thomson, D., Wood, N.I., Hinks, T., Gillingwater, T.H., Wishart, T.M., Court, F.A. and Morton, A.J. (2004) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci., 20, 3092-3114.
28. Bjorkqvist, M., Petersen, A., Bacos, K., Isaacs, J., Norlen, P., Gil, J., Popovic, N., Sundler, F., Bates, G.P., Tabrizi, S.J. et al. (2006) Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 15, 1713-1721.
29. Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science, 2, 2.
30. Nucifora, F.C., Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
31. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
32. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
33. Wyttenbach, A., Swartz, J., Kita, H., Thykjaer, T., Carmichael, J., Bradley, J., Brown, R., Maxwell, M., Schapira, A., Orntoft, T.F. et al. (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet., 10, 1829-1845.
34. Zhai, W., Jeong, H., Cui, L., Krainc, D. and Tjian, R. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell, 123, 1241-1253.
35. Picconi, B., Passino, E., Sgobio, C., Bonsi, P., Barone, I., Ghiglieri, V., Pisani, A., Bernardi, G., Ammassari-Teule, M. and Calabresi, P. (2006) Plastic and behavioral abnormalities in experimental Huntington's disease: A crucial role for cholinergic interneurons. Neurobiol. Dis., 22(1), 143-152.
36. Lawrence, A.D., Hodges, J.R., Rosser, A.E., Kershaw, A., ffrench-Constant, C., Rubinsztein, D.C., Robbins, T.W. and Sahakian, B.J. (1998) Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain, 121, 1329-1341.
37. Lione, L.A., Carter, R.J., Hunt, M.J., Bates, G.P., Morton, A.J. and Dunnett, S.B. (1999) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci., 19, 10428-10437.
38. Murphy, K.P., Carter, R.J., Lione, L.A., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. and Morton, A.J. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci., 20, 5115-5123.
39. Dokla, C.P. and Thal, L.J. (1988) Effect of cholinesterase inhibitors on Morris water task behavior following lesions of the nucleus basalis magnocellularis. Behav. Neurosci., 102, 861-871.
40. Mach, M., Grubbs, R.D., Price, W.A., Paton, S.J. and Lucot, J.B. (2004) Behavioral changes after acetylcholinesterase inhibition with physostigmine in mice. Pharmacol. Biochem. Behav., 79, 533-540.
41. Papalexi, E., Persson, A., Bjorkqvist, M., Petersen, A., Woodman, B., Bates, G.P., Sundler, F., Mulder, H., Brundin, P. and Popovic, N. (2005) Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci., 22, 1541-1546.
42. Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl Acad. Sci. USA, 76, 4350-4354.
43. Li, Y. (1996) Rabphilin-3A is transported with fast anterograde axonal transport and associated with synaptic vesicles. Synapse, 23, 79-88.
44. Gundersen, H.J., Bendtsen, T.F., Korbo, L., Marcussen, N., Moller, A., Nielsen, K., Nyengaard, J.R., Pakkenberg, B., Sorensen, F.B., Vesterby, A. et al. (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Apmis, 96, 379-394.
45. Morris, R. (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods, 11, 47-60.
46. Ellman, G.L., Courtney, K.D., Andres, V., Jr and Feather-Stone, R.M. (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7, 88-95.